publication date: Oct. 30, 2014

Study: Angiopoietin-2 Levels May Predict Lenvatinib Response

 

A new analysis from the phase III SELECT trial of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer shows that the level of baseline angiopoietin-2 may be a predictive factor for lenvatinib response, tumor shrinkage and prolonged progression free survival. Angiopoietin-2 regulates the formation tumor blood vessels.

A second subgroup analysis from SELECT shows a statistically significant correlation between hypertension and PFS in people with radioiodine-refractory differentiated thyroid cancer. The analyses were presented at the European Society for Medical Oncology 2014 Congress.

Hypertension is a known adverse event of vascular endothelial growth factor receptor inhibition and a biomarker for tyrosine kinase inhibitor efficacy in renal cell carcinoma treatment. In the SELECT study, 73 percent of lenvatinib treated patients experienced hypertension.

“To date, there are no established prognostic or predictive biomarkers for radioiodine-refractory differentiated thyroid cancer or its treatment, so these studies are crucial in helping to understand further this disease and the best approach to treatment,” said Lori Wirth, assistant professor of medicine at Harvard Medical School and medical director of the Center for Head and Neck Cancers at Massachusetts General Hospital.

“Although hypertension is a significant adverse event that must be carefully monitored and managed, it may be an important indicator of the efficacy of treatments such as lenvatinib,” she said. “Further studies are needed to investigate hypertension as a predictive indicator of lenvatinib response so that people with radioiodine-refractory differentiated thyroid cancer can be managed appropriately to ensure they get the most out of their treatment.”

A third subgroup analysis characterized the change in tumor size in radioiodine-refractory differentiated thyroid cancer. Patients who received lenvatinib treatment for one … Continue reading CCL Oct – Thyroid Cancer

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.